跳至主要内容
临床试验/NCT06388785
NCT06388785进行中(未招募)不适用

Post-vaccination Surveillance for Monitoring the Adverse Events Following Immunisation With QDENGA in a Real-world Setting in Malaysia (PRIME-Q)

Takeda4 个研究点 分布在 1 个国家目标入组 2,000 人开始时间: 2024年9月26日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
2,000
试验地点
4
主要终点
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

研究概览

简要总结

The main aim of this study is to collect the number and type of medical problems (adverse events) after vaccination with QDENGA in Malaysia and to learn more about such medical problems after vaccination. Another aim of this study is to collect the number of persons vaccinated with QDENGA who need to stay in the hospital because of severe dengue fever.

No vaccination will be given as part of this study. The study will only collect data of persons already vaccinated with QDENGA who agree to participate.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
4 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Participants who have received at least one dose of QDENGA vaccine in Malaysia during the study period.
  • Participants or their legally authorized representative (LARs) with a functioning phone number.

排除标准

  • No exclusion criteria will be applied for this study.

结局指标

主要结局

Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

时间窗: From 14 days after first vaccination up to 15 months

An AE is any untoward medical occurrence in a participant administered a studied drug and which does not necessarily have to have a causal relationship with the vaccine. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, a new disease or worsening in severity or frequency of a concomitant disease, temporally associated with the use of a studied drug, whether or not the event is considered causally related to the use of the product. An SAE is any untoward medical occurrence that at any dose: results in death, life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent, significant disability/incapacity, a congenital abnormality/birth defect, an important medical event in the opinion of the healthcare provider, may jeopardize the participant or may require intervention to prevent one of the other outcomes listed in the definition above.

次要结局

  • Number of Participants who Require Hospitalization for Severe Dengue Diagnosed by Healthcare Provider (HCP)(From 14 days after first vaccination up to 15 months)

研究者

发起方
Takeda
申办方类型
Industry
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验

A Study to Monitor the Adverse Events of QDENGA... | 临床试验